The ataxia telangiectasia mutated (ATM ) gene is known to be activated by DNA damage and involved in cell cycle arrest, apoptosis and DNA repair. Therefore, ATM gene polymorphisms may act as important factors predicting individual susceptibility to lung cancer. To evaluate the role of ATM gene polymorphisms in lung cancer development, genotypes of the ATM polymorphisms, 24518A>G, IVS21 2 77C>T, IVS61 2 55T>C, and IVS62 1 60G>A, were determined in 616 lung cancer patients and 616 cancer-free controls. When the effects of selected ATM genotypes were evaluated separately, only one ATM genotype (IVS62 1 60G>A) showed an association with lung cancer risk. Subjects with the A allele at the site (IVS62 1 60G>A) have significantly higher risk of lung cancer than those with the G allele [odds ratio (OR) 5 1.6, 95% confidence interval (CI) 1.1 -2.1]. When the haplotypes of four ATM single nucleotide polymorphism sites (24518A>G, IVS21 2 77C>T, IVS61 2 55T>C and IVS62 1 60G>A) were studied, the ATTA haplotype showed significantly increased risk of lung cancer compared with the GCCA haplotype, the most common haplotype (OR 5 7.6, 95% CI 1.7 -33.5). Furthermore, subjects with the (NN)TA haplotype showed highly significant and increased risk of lung cancer when compared with those without the (NN)TA haplotype (OR 5 13.2, 95% CI 3.1 -56.1). Therefore, our results suggest that polymorphisms or haplotypes of the ATM gene play an important role in the development of lung cancer.
INTRODUCTION
Ataxia telangiectasia mutated (ATM) is the product of the gene mutated in patients with the autosomal recessive disorder ataxia telangiectasia (AT) and a member of the phosphatidylinositol 3/phosphatidylinositol 4-kinase family (1, 2) . This protein is known to be activated by DNA damage caused by ionizing radiation or reactive oxygen intermediates to induce the transactivation of various proteins that function in cell cycle arrest, apoptosis, DNA repair and centrosome duplication (3 -5) . In particular, ATM plays an important regulatory role in phosphorylation of p53, a tumor suppressor, thereby abolishing p53 -Mdm2 interaction and allowing p53 to accumulate (6) . ATM also phosphorylates Mdm2 which interferes with the nucleo-cytoplasmic shuttling of the Mdm2-p53 complex and contributes to p53 stabilization (7) . In addition, ATM functions as a regulator of a wide variety of downstream proteins, including tumor suppressor BRCA1, checkpoint kinase # The Author 2006. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org CHK2, checkpoint protein RAD50 and DNA repair protein NBS1 (1, 2) .
Lung cancer is a leading cause of cancer-related death worldwide. Extensive epidemiological data clearly establish cigarette smoking as the major cause of this malignancy. Although up to 90% of lung cancer is attributable to smoking, only 5-10% of smokers develop lung cancer (8) . This observation suggests that individual variation may determine susceptibility to lung cancer. Individual susceptibility to lung cancer varies with the presence of single nucleotide polymorphisms (SNPs) in genes related to cellular cycling such as cell cycle arrest and apoptosis (9) . Therefore, ATM gene polymorphisms may act as important factors indicating individual susceptibility to lung cancer. A number of studies have evaluated the association between ATM gene polymorphisms and cancer development. However, ATM gene polymorphisms have not been studied about association with lung cancer, although several ATM polymorphisms have been suggested to pre-dispose those with specific genotypes or haplotypes to increased risk of breast, ovarian cancer or hereditary non-polyposis colorectal cancer (10 -15) .
In this study, we explored genetic polymorphisms of ATM to evaluate association with lung cancer risk in a case -control study of a Korean population.
RESULTS
Characteristics of lung cancer cases and control subjects were shown in Table 1 . Age, sex and family history of cancer were not significantly different between cases and controls. However, body mass index (BMI) and smoking were shown to affect the odds ratio (OR) of lung cancer [BMI: OR ¼ 1.1, 95% confidence interval (CI) 1.1 -1.1; smoking: OR ¼ 2.4, 95% CI 1.9 -3.1, respectively].
The allele frequencies of four loci (24518A, 0.43; IVS21 2 77C, 0.63; IVS61 2 55T, 0.46 and IVS62 þ 60G, 0.44) of ATM gene in this Korean population were shown to be different from those of the SNP500Cancer database (0.55, 0.29, 0.57 and 0.67, respectively).
When we tested Hardy -Weinberg equilibrium (HWE) of ATM genotypes, both cases and controls were found to be on the HWE (all of four SNPs, P . 0.05). Moreover, in the analysis of the relative disequilibrium (D 0 ) between two from four sites, all sites were found to be strongly linked to each other (D 0 ! 0.84, P , 0.0001) (Fig. 1 ). When the effects of the selected ATM genotypes on lung cancer risk were evaluated separately (Table 2) , only one ATM genotype (rs664143) was shown to affect lung cancer risk. Subjects with the A allele at the site (IVS62 þ 60G.A) have significantly higher risk of lung cancer than those with only the G allele (adjusted OR ¼ 1.6, 95% CI 1.1 -2.1).
When haplotypes were composed of four ATM SNP sites (rs189037, rs664677, rs664982 and rs664143), the distributions of haplotypes were shown to be significantly different between cases and controls (P , 0.001) ( Table 3) . Moreover, subjects with the ATTA haplotype showed significantly increased risk of lung cancer compared with those with GCCA, the most common haplotype (adjusted OR ¼ 7.6, 95% CI 1.7 -33.5). In particular, the ACTA haplotype showed large difference between cases and controls with the absence of control subject, although its risk did not be expressed. The GCTA haplotype also showed the absence of control subject like ACTA. Because all three haplotypes (ATTA, ACTA and GCTA) carry the sequence (NN)TA, we estimated the effect of the (NN)TA sequence on lung cancer development. Subjects with the (NN)TA haplotype showed highly significant and increased risk of lung cancer compared with those without the (NN)TA haplotype (adjusted OR ¼ 13.2, 95% CI 3.1 -56.1) ( Table 4 ). In addition, subjects with a (NN)TA/(NN)TA diplotype were not found in either cases or controls.
Lung cancers are composed of heterogenous cell types, and the baseline characteristics are different according to the cell type. For this reason, the effect of the (NN)TA haplotype on lung cancer risk was estimated according to the cell type of lung cancer. Non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) showed very different effect of the (NN)TA haplotype on each cancer development (NSCLC: adjusted OR ¼ 15.3, 95% CI 3.6-65.0 and SCLC: adjusted OR ¼ 2.1, 95% CI 0.2 -23.3, respectively).
DISCUSSION
In a study on the cancer risks in heterozygous ATM mutation carriers, the relative risk for cancers except breast cancer was 2.05 (95% CI 1.09-3.84) in female carriers (16) . Moreover, another study reported a 100-fold increased risk of developing cancer in AT patients compared with the general population (17) . Our results that the IVS62 þ 60G.A polymorphism or The most common ATM mutations in a large multiethnic cohort were reported to be associated with specific SNP haplotypes (18) . In addition, the typical phenotypes in AT patients such as pre-disposition to cancer and chromosomal instability were found to be caused by ATM alleles that affect mRNA splicing or gene expression to either truncate or severely destabilize the ATM protein (19 -21) . These study results suggest the possibility that specific haplotypes related to the activity of the ATM gene may induce low expression or destabilization of the ATM protein and thereby increase the risk of cancer. In this study, the associations between one SNP (24518A . G) in the promoter and three intronic SNPs (IVS21 2 77C . T, IVS61 þ 55T.C and IVS62 þ 60G.A) and lung cancer risk were evaluated and all four SNPs have a possibility that may regulate ATM protein activity due to regulation function of promoter and intron as shown in most genes. Our finding that the specific haplotype (NN)TA which consisted of these SNPs increases the risk of lung cancer strongly supports previous study results that specific genotypes or haplotypes of ATM may play an important role in carcinogenesis through expression regulation or alternative splicing of the ATM gene (22) . In fact, the last two sites of (NN)TA are very close loci (178 bp distance) existing in two introns interrupted by exon 61. Moreover, when we examined the effects of two sites on splicing using the webbased tool (Improbizer, http://www.cse.ucsc.edu/%7Ekent/ improbizer/improbizer.html NumMotifs and MEME version 3.5.0, http://meme.sdsc.edu/meme/website/meme.html), data obtained from these tools showed that both sites exist in proteinbinding motifs having a potential as binding sites of intronic splicing enhancer or repressor, indicating a possibility that both sites may be related to splicing process of exon 61 to lead to inaccurate splicing. However, this hypothesis should be confirmed through a variety of functional studies including RT -PCR of mRNA using biosamples obtained from subjects with the haplotype.
Traditional genetic analysis methods have not shown sensitivity for a genetic contribution when it is subtle or when several genes are working together in multifactorial diseases such as cancer (23) . In fact, the attempts to correlate singlelocus alleles with cancer development have produced mixed results. To solve this problem and increase statistical sensitivity, the study of haplotypes has been suggested as a powerful methodology for the detection of the relationship of genes with diseases (23, 24) . In addition, haplotypes consisting of SNP sites in a large gene such as ATM were found to be useful (23) . In particular, linkage disequilibrium (LD)-based strategies for detection of the genetic contributions to common diseases may be a very powerful approach. In this study, pairwise LD among four polymorphisms in the ATM gene was very high (D 0 ! 0.84, P , 0.0001). Moreover, the closely linked (NN)TA haplotype showed highly increased risk of lung cancer (adjusted OR ¼ 13.2, 95% CI 3.1 -56.1). In particular, subjects with an (NN)TA/(NN)TA diplotype were not observed either in cases or in controls. Our data also showed considerable difference between NSCLC and SCLC in regard to the effect of the (NN)TA haplotype on lung cancer risk. Because NSCLC and SCLC are different diseases in every aspect from cellular origin, genetic/molecular In conclusion, the results of this study suggest that genetic polymorphisms of ATM play an important role in lung cancer development. However, we need to clearly understand the function of SNPs or haplotypes in ATM in the development of lung cancer through laboratory research.
MATERIALS AND METHODS

Study population
A total of 616 patients with newly diagnosed lung cancer at Chungbuk National University Hospital, Dankook University Hospital and Inha University Hospital between 2001 and 2003 were recruited. There were no age, histological or stage restrictions, and all lung cancer cases were histologically confirmed. The control subjects consisted of non-cancer patients admitted to the same hospitals or participants in the health checkup program of each hospital. They were individually matched to the cases by age (+2 years) and sex. Detailed information on diet, smoking habits, lifestyle, weight, height, medical treatment and other socio-economic characteristics were collected by trained interviewers using a structured questionnaire. The study protocol was approved by the institutional review board at each hospital, and written informed consent was provided by all study participants. Venous blood samples from all subjects were collected into heparinized tubes and stored at 2708C until used for DNA extraction.
Genotyping
In a study on SNP using limited number of subjects, low minor allele frequency of the SNP may lead to null result although the SNP is meaningful for the risk of target disease. Therefore, we first selected five ATM SNPs (rs189037, rs664677, rs600329, rs664982 and rs664143) which have .10% minor allele frequencies based on the SNP500Cancer database (http://snp500cancer.nci.nih.gov/home.cfm) and then Dan Stram's haplotype-tagging SNP program (tagSNPsv2.exe) was used to determine the best set of haplotype-tagging SNPs. Of these five SNPs, four (rs189037, rs664677, rs664982 and rs664143; min RSQ ¼ 0.9936) were selected and successfully genotyped.
DNA was extracted from whole blood sample using a QIAamp DNA Blood Mini Kit (Qiagen, Valencia, CA, USA). SNP genotyping was performed by SNP-IT TM assays (for rs664677, rs664982 and rs664143) using SNPstream 25K
w System (Orchid Biosciences, Princeton, NJ, USA) and single base primer extension assay (for rs189037) using SNaPShot assay kit (ABI, Foster City, CA, USA) according to manufacturers' recommendation.
In SNP-IT assays, the genomic DNA region spanning the polymorphic site was PCR-amplified using one phosphothiolated primer and one regular PCR primer. The amplified PCR products were then digested with exonuclease (Amersham Biosciences, Uppsala, Sweden). The 5 0 phosphothiolates were used in this study to protect one strand of the PCR product from exonuclease digestion. The singlestranded PCR template generated from exonuclease digestion was overlaid onto a 384-well plate that was pre-coated covalently with the primer extension primers, SNP-IT primers (Table 5 ). These SNP-IT primers were designed to hybridize immediately adjacent to the polymorphic site. After hybridization of template strands, SNP-IT primers were then extended by a single base with DNA polymerase at the polymorphic site of interest. The extension mixtures contained two labeled terminating nucleotides (one FITC, one biotin) and two unlabeled terminating nucleotides. The final single base incorporated was identified with serial colorimetric reactions with anti-Fluorescein-AP (Roche, Basel, Switzerland) and streptavidin-HRP (Pierce, Rockford, IL, USA), respectively. The results of blue and/or yellow color developments were analyzed with an ELISA reader and the final genotyping (allele) calls were made with the QCReview program. In the single base primer extension assay, the genomic DNA region containing both of the SNP was amplified with a PCR reaction. Each PCR reaction contained: 10.0 ng of DNA, 1 Â PCR buffer, 0.125 U of AmpliTaq Gold DNA polymerase (ABI), 3.0 mM MgCl 2 , 0.25 mM of each dNTP and 0.5 pmol of each primer in 10 ml reaction volume. Reactions were incubated at 958C for 10 min, then cycled 30 times at (958C for 30 s, 608C for 1 min, 728C for 1 min) followed by 728C for 5 min. After amplification, the PCR products were treated with 1 U of shrimp alkaline phosphatase (SAP) (Roche) and exonuclease I (USB Corporation) at 378C for 60 min and 728C for 15 min to purify the amplified products. One microliter of the purified amplification products were added to a SNaPshot Multiplex Ready reaction mixture containing 0.15 pmol of genotyping primer ( Table 5 ). The primer extension reaction was carried out for 25 cycles at 968C for 10 s, 508C for 5 s and 608C for 30 s. The reaction products were treated with 1 U of SAP at 378C for 1 h and 728C for 15 min to remove excess fluorescent dye terminators. One microliter of the final reaction samples containing the extension products were added to 9 ml of Hi-Di formamide (ABI). The mixture was incubated at 958C for 5 min, followed by 5 min on ice and then analyzed by electrophoresis in ABI Prism 3730 DNA analyzer. Results were analyzed using Gene Mapper software (ABI).
All genotyping was done blindly to the case -control status and the repeatability test was conducted for 5% of total subjects, resulting in a 98.9% concordance rate.
Statistical analysis
Unconditional logistic regression was used to estimate ORs and 95% CI according to the ATM gene polymorphisms in lung cancer patients and control subjects. Incomplete data missing at least one of four SNPs were excluded, and then individual haplotypes were estimated from genotype data using the PHASE program (ver. 2.0.2). The x 2 test was used to compare the distribution of haplotypes in the cases and the controls. To find out whether each SNP site are on the HWE, the distributions of observed genotype frequency and expected genotype frequency, which was calculated from observed allele frequency, were compared using the x 2 test. Pairwise LD among four polymorphic sites was estimated as relative disequilibrium (D 0 ) (13) . A probability level of 0.05 was used as criterion for statistical significance. SAS, version 8.1 (SAS Institute Inc., Cary, NC, USA), was used for statistical analysis.
